The European Medicines Agency this week recommended that five new products be granted EU marketing approval.

Aerie is already exploring its pricing strategy for Roclanda as the European Medicines Agency this week decides whether the intraocular pressure treatment should be approved in Europe.

A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.

Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.